CIMERLI — SANDOZ INC, approved 2024-05-21 (BLA761165).
20,521 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.